Literature DB >> 10670627

Transplantation of highly differentiated immortalized human hepatocytes to treat acute liver failure.

N Kobayashi1, M Miyazaki, K Fukaya, Y Inoue, M Sakaguchi, T Uemura, H Noguchi, A Kondo, N Tanaka, M Namba.   

Abstract

BACKGROUND: Temporary support of a damaged liver by a bioartificial liver (BAL) devise is a promising approach for the treatment of acute liver failure. Although human primary hepatocytes are an ideal source of hepatic function in BAL, shortage of human livers available for hepatocyte isolation is the limiting factor for the use of this modality. A clonal human hepatocyte cell line that can grow economically in culture and exhibit liver-specific functions should be an attractive solution to this problem.
METHODS: To test this alternative, primary human fetal hepatocytes were immortalized using Simian virus 40 large T antigen. To investigate the potential of the immortalized cells for BAL, we transplanted the cells into the spleen of adult rats and performed a 90% hepatectomy 12 hr later.
RESULTS: One of the cloned human liver cell lines, OUMS-29, showed highly differentiated liver functions. Intrasplenic transplanting of 20x10(6) OUMS-29 cells protected the animals from hyperammonemia and the associated hepatic encephalopathy. Survival was significantly prolonged in 90% of hepatectomized rats receiving OUMS-29 cells.
CONCLUSIONS: A highly differentiated immortalized human hepatocyte cell line, OUMS-29, was able to provide metabolic support during acute liver failure induced by 90% hepatectomy in rats. Essentially unlimited availability of OUMS-29 cells may be clinically useful for BAL treatment.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10670627     DOI: 10.1097/00007890-200001270-00002

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Sorafenib enhances proteasome inhibitor-induced cell death via inactivation of Akt and stress-activated protein kinases.

Authors:  Yuichi Honma; Satoshi Shimizu; Tetsuo Takehara; Masaru Harada
Journal:  J Gastroenterol       Date:  2013-03-31       Impact factor: 7.527

2.  The Wilson disease protein ATP7B resides in the late endosomes with Rab7 and the Niemann-Pick C1 protein.

Authors:  Masaru Harada; Takumi Kawaguchi; Hiroto Kumemura; Kunihiko Terada; Haruaki Ninomiya; Eitaro Taniguchi; Shinichiro Hanada; Shinji Baba; Michiko Maeyama; Hironori Koga; Takato Ueno; Koh Furuta; Tatsuo Suganuma; Toshihiro Sugiyama; Michio Sata
Journal:  Am J Pathol       Date:  2005-02       Impact factor: 4.307

3.  Expression, purification and bioactivity of human augmenter of liver regeneration.

Authors:  Yang-De Zhang; Jian Zhou; Jin-Feng Zhao; Jian Peng; Xiao-Dong Liu; Xin-Sheng Liu; Ze-Ming Jia
Journal:  World J Gastroenterol       Date:  2006-07-21       Impact factor: 5.742

4.  Pigment epithelium-derived factor inhibits lysosomal degradation of Bcl-xL and apoptosis in HepG2 cells.

Authors:  Takumi Kawaguchi; Sho-Ichi Yamagishi; Minoru Itou; Koji Okuda; Shuji Sumie; Ryoko Kuromatsu; Masahiro Sakata; Mitsuhiko Abe; Eitaro Taniguchi; Hironori Koga; Masaru Harada; Takato Ueno; Michio Sata
Journal:  Am J Pathol       Date:  2009-11-30       Impact factor: 4.307

5.  Loss of exon 4 in a human T-cell factor-4 isoform promotes hepatic tumourigenicity.

Authors:  Yoshito Tomimaru; Chelsea Q Xu; Sarah B Nambotin; Tao Yan; Jack R Wands; Miran Kim
Journal:  Liver Int       Date:  2013-05-06       Impact factor: 5.828

Review 6.  Cellular Transplantation for Liver Diseases.

Authors:  Elizabeth Jameson
Journal:  Gastroenterology Res       Date:  2008-11-20

7.  A glycosaminoglycan based, modular tissue scaffold system for rapid assembly of perfusable, high cell density, engineered tissues.

Authors:  Ramkumar Tiruvannamalai-Annamalai; David Randall Armant; Howard W T Matthew
Journal:  PLoS One       Date:  2014-01-20       Impact factor: 3.240

8.  Zinc Attenuates the Cytotoxicity of Some Stimuli by Reducing Endoplasmic Reticulum Stress in Hepatocytes.

Authors:  Masashi Kusanaga; Shinji Oe; Noriyoshi Ogino; Sota Minami; Koichiro Miyagawa; Yuichi Honma; Masaru Harada
Journal:  Int J Mol Sci       Date:  2019-05-03       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.